O'Brien P - Search Results

1

Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study.

Chua BH, Link EK, Kunkler IH, Whelan TJ, Westenberg AH, Gruber G, Bryant G, Ahern V, Purohit K, Graham PH, Akra M, McArdle O, O'Brien P, Harvey JA, Kirkove C, Maduro JH, Campbell ID, Delaney GP, Martin JD, Vu TTT, Muanza TM, Neal A, Olivotto IA; BIG 3–07/TROG 07.01 trial investigators. Chua BH, et al. Lancet. 2022 Aug 6;400(10350):431-440. doi: 10.1016/S0140-6736(22)01246-6. Lancet. 2022. PMID: 35934006 Clinical Trial.

2

Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial.

King MT, Link EK, Whelan TJ, Olivotto IA, Kunkler I, Westenberg AH, Gruber G, Schofield P, Chua BH; BIG 3-07/TROG 07.01 trial investigators. King MT, et al. Lancet Oncol. 2020 May;21(5):685-698. doi: 10.1016/S1470-2045(20)30085-1. Epub 2020 Mar 20. Lancet Oncol. 2020. PMID: 32203696 Clinical Trial.

3

Can we predict plan quality for external beam partial breast irradiation: results of a multicenter feasibility study (Trans Tasman Radiation Oncology Group Study 06.02).

Kron T, Willis D, Link E, Lehman M, Campbell G, O'Brien P, Chua B. Kron T, et al. Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):817-24. doi: 10.1016/j.ijrobp.2013.07.036. Epub 2013 Sep 21. Int J Radiat Oncol Biol Phys. 2013. PMID: 24064318 Clinical Trial.

4

How should we introduce high-dose chemotherapeutic strategies into the adjuvant management of high-risk breast cancer in Australasia?

Back M, Delaney G, Denham J, Graham P, Hamilton C, Morgan G, O'Brien P, Yuile P. Back M, et al. Aust N Z J Surg. 1998 Jan;68(1):10-5. doi: 10.1111/j.1445-2197.1998.tb04628.x. Aust N Z J Surg. 1998. PMID: 9440448 Review.

5

Weekly carboplatin reduces toxicity during synchronous chemoradiotherapy for Merkel cell carcinoma of skin.

Poulsen M, Walpole E, Harvey J, Dickie G, O'Brien P, Keller J, Tripcony L, Rischin D. Poulsen M, et al. Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1070-4. doi: 10.1016/j.ijrobp.2008.02.076. Epub 2008 Aug 15. Int J Radiat Oncol Biol Phys. 2008. PMID: 18707820 Clinical Trial.

6

Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05).

Roos DE, Turner SL, O'Brien PC, Smith JG, Spry NA, Burmeister BH, Hoskin PJ, Ball DL; Trans-Tasman Radiation Oncology Group, TROG 96.05. Roos DE, et al. Radiother Oncol. 2005 Apr;75(1):54-63. doi: 10.1016/j.radonc.2004.09.017. Epub 2004 Oct 28. Radiother Oncol. 2005. PMID: 15878101 Clinical Trial.

7

A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial.

Ball D, Bishop J, Smith J, O'Brien P, Davis S, Ryan G, Olver I, Toner G, Walker Q, Joseph D. Ball D, et al. Radiother Oncol. 1999 Aug;52(2):129-36. doi: 10.1016/s0167-8140(99)00093-6. Radiother Oncol. 1999. PMID: 10577698 Clinical Trial.

8

Factors influencing outcome following radio-chemotherapy for oesophageal cancer. The Trans Tasman Radiation Oncology Group (TROG).

Denham JW, Burmeister BH, Lamb DS, Spry NA, Joseph DJ, Hamilton CS, Yeoh E, O'Brien P, Walker QJ. Denham JW, et al. Radiother Oncol. 1996 Jul;40(1):31-43. doi: 10.1016/0167-8140(96)01762-8. Radiother Oncol. 1996. PMID: 8844885 Clinical Trial.

9

Prospective Phase II trial of radiation therapy in localised non-gastric marginal zone lymphoma with prospective evaluation of autoimmunity and Helicobacter pylori status: TROG 05.02/ALLG NHL15.

MacManus MP, Roos D, O'Brien P, Capp A, Wirth A, Tsang R, Bressel M, Lade S, Seymour JF. MacManus MP, et al. Eur J Cancer. 2021 Jul;152:129-138. doi: 10.1016/j.ejca.2021.05.004. Epub 2021 Jun 5. Eur J Cancer. 2021. PMID: 34098462 Clinical Trial.

10

Costing the components of pain management: analysis of Trans-Tasman Radiation Oncology Group trial (TROG 96.05): one versus five fractions for neuropathic bone pain.

Pollicino CA, Turner SL, Roos DE, O'Brien PC. Pollicino CA, et al. Radiother Oncol. 2005 Sep;76(3):264-9. doi: 10.1016/j.radonc.2005.07.003. Radiother Oncol. 2005. PMID: 16153729

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,875 results

Search Page